Dragon Pharma, Europe
MK 2866
Oral · 25 mg/tab · 100 tabs
$140.00
Compound ID
Ostarine
Dosage
10–25 mg/day
Concentration
25 mg/tablet
Form
100 Tablets × 25 mg
Half-life
Approximately 24 hours
Properties
Shipping
Not available in this combination
Product overview
Dragon Pharma Ostarine MK-2866 25mg — Versatile SARM for Lean Hypertrophy, Body Recomposition & Connective Tissue Repair
Dragon Pharma Ostarine MK-2866 25mg stands as the most extensively researched and clinically validated selective androgen receptor modulator in the performance enhancement landscape, offering an exceptional balance of anabolic efficacy, safety margins, and physiological versatility. Engineered for both novice users entering the world of advanced supplementation and seasoned athletes seeking a reliable, multi-functional compound, MK-2866 delivers measurable improvements in lean tissue accretion, adipose reduction, and musculoskeletal resilience without the systemic burdens of traditional anabolic steroids. Its well-documented affinity for androgen receptors in muscle and bone tissue, combined with documented collagen synthesis stimulation, positions it as a uniquely comprehensive agent for physique development and injury recovery alike. Dragon Pharma's precisely manufactured 25mg tablets, independently verified at 23.89mg active content, provide a pharmaceutical-grade platform for individuals prioritizing sustainable results alongside long-term joint and tendon health.
What is Dragon Pharma MK-2866?
MK-2866, universally recognized as Ostarine, is a non-steroidal selective androgen receptor modulator originally developed to address muscle wasting conditions, osteoporosis, and age-related sarcopenia. Unlike anabolic steroids, which indiscriminately activate androgen receptors across prostate, skin, sebaceous glands, and hepatic tissues, Ostarine exhibits a markedly higher binding preference for receptors located within skeletal muscle, bone matrix, and connective tissue. This tissue selectivity underpins its favorable therapeutic index, enabling significant nitrogen retention, protein synthesis upregulation, and osteoblastic activity while minimizing androgenic complications such as virilization, prostate enlargement, or dermatological disturbances. Dragon Pharma's 25mg oral formulation represents one of the highest commercially available concentrations, providing flexible dosing protocols that accommodate therapeutic joint repair, conservative recomposition, and more aggressive hypertrophic objectives within a single product.
Key Benefits / Effects
- Sustainable Lean Hypertrophy: Users consistently report steady, high-quality mass accretion of 5–10 pounds per cycle, characterized by minimal subcutaneous water retention and durable myofibrillar development.
- Accelerated Adipose Reduction: Enhanced insulin sensitivity and elevated metabolic rate improve carbohydrate utilization efficiency and fatty acid oxidation, creating a favorable environment for body recomposition even in modest caloric deficits.
- Connective Tissue Regeneration: Ostarine's stimulation of collagen synthesis and elevation of bone mineral density strengthens tendons, ligaments, and articular surfaces, reducing injury susceptibility and accelerating recovery from chronic overuse or acute strain.
- Consistent Strength Progression: Improved neuromuscular efficiency and increased contractile tissue support progressive overload capacity, enabling heavier lifts and more productive training sessions throughout the cycle.
- Muscular Endurance Enhancement: Delayed onset of intramuscular fatigue allows for increased training volume, additional repetitions per set, and shortened inter-set recovery without compromising form or intensity.
- Anti-Catabolic Protection: Potent anabolic signaling preserves existing lean tissue during hypocaloric cutting phases, extended fasting, or post-cycle hormonal transitions, preventing the muscle degradation that typically accompanies energy restriction.
How Dragon Pharma MK-2866 Works
Ostarine functions through high-affinity binding to androgen receptors in skeletal myocytes, osteoblasts, and fibroblasts, initiating a conformational change that facilitates nuclear translocation and subsequent interaction with androgen response elements on DNA. This genomic activation upregulates transcription of muscle-specific genes involved in protein synthesis, satellite cell proliferation, and myonuclear addition. Concurrently, MK-2866 enhances nitrogen retention within muscle tissue, creating a sustained positive nitrogen balance essential for anabolism. In connective tissue, the compound stimulates type I and type III collagen production within tendons and ligaments, improving tensile strength and reducing the inflammatory cascade associated with repetitive mechanical loading. The compound's selectivity arises from its differential coactivator recruitment profile and tissue-specific metabolic handling, which limit activation of androgenic pathways in non-target tissues. The net physiological result is robust yet manageable hypertrophy, improved bone turnover markers, accelerated soft-tissue repair, and favorable metabolic adaptation without the systemic androgenic load characteristic of testosterone derivatives.
Usage Information
Dragon Pharma MK-2866 is supplied as 25mg oral tablets with a pharmacokinetic half-life of approximately 24 hours, supporting convenient once-daily administration at any consistent time. Therapeutic and beginner users typically employ 10–15mg daily for joint healing, muscle preservation, and gentle recomposition with minimal suppression risk. Intermediate practitioners seeking noticeable hypertrophy and fat-loss outcomes generally utilize 20–25mg daily, representing the standard effective range for most physique objectives. Advanced users may escalate to 25–30mg daily, though suppression severity and diminishing returns increase proportionally beyond the 25mg threshold. Standard cycle duration spans 8–12 weeks, with longer protocols requiring more vigilant health monitoring. Dosing may occur with or without food, though consistent daily timing optimizes steady-state plasma concentrations. Post-Cycle Therapy is recommended for any cycle exceeding 8 weeks or utilizing doses above 20mg daily to restore endogenous testosterone production efficiently.
Quality & Manufacturing
Dragon Pharma enforces stringent analytical and manufacturing standards, with each Ostarine batch subjected to independent third-party laboratory testing for identity, purity, and potency verification. Recent analytical results confirmed an actual MK-2866 content of 23.89mg per tablet—a figure well within accepted pharmaceutical tolerance for a 25mg labeled product. In the unregulated SARM marketplace, where underdosing, mislabeling, and contamination with prohormones or anabolic steroids are endemic, this level of dosing accuracy and transparency is essential. Athletes integrating Ostarine into rehabilitation, recomposition, or bulking protocols can do so with confidence that each tablet delivers the intended pharmacological payload, supporting predictable outcomes and responsible side-effect management.
Possible Side Effects / Safety Information
- Mild Testosterone Suppression: Ostarine exerts dose-dependent negative feedback on the hypothalamic-pituitary-gonadal axis. At 10–15mg daily, suppression is typically minimal; at 25mg and above, it becomes more pronounced, necessitating structured PCT for cycles exceeding 8 weeks.
- Low Estrogen Manifestations: As circulating testosterone declines during suppression, downstream estrogen conversion decreases, potentially producing transient lethargy, diminished libido, and mild joint discomfort in longer or higher-dose cycles.
- Modest Lipid Profile Alteration: Reductions in high-density lipoprotein (HDL) cholesterol may occur, though the effect is generally milder than with oral steroids or more aggressive SARMs. Cardiovascular support through omega-3 supplementation and dietary fiber is advisable.
- Minimal Androgenic Expression: Due to high tissue selectivity, acne, accelerated hair loss, and other androgenic side effects are exceedingly rare and typically limited to genetically hypersensitive individuals at elevated doses.
- Absence of Hepatotoxicity: MK-2866 is not a C17-alpha alkylated compound and poses negligible stress to hepatic enzyme systems, making it significantly safer for liver health than traditional oral anabolic steroids.
Why Choose Dragon Pharma MK-2866?
The SARM marketplace is saturated with counterfeit, underdosed, and dangerously mislabeled products that compromise both results and user safety. Dragon Pharma distinguishes itself through verified analytical transparency, with independent testing confirming 23.89mg potency per tablet. This precision enables athletes to design protocols with mathematical certainty rather than guesswork, ensuring that dosing strategies align with clinical research and real-world efficacy data. For individuals seeking a research-backed, tissue-selective agent capable of delivering sustainable lean mass, connective tissue repair, and metabolic optimization without the systemic burdens of traditional steroids, Dragon Pharma Ostarine represents the benchmark of quality, versatility, and reliability within its class.
Lab Report
Lab Report: 23.89 mg/tab
18 April 2025
25 mg/tab of label claim
| Analysis Date | 2025-04-18 |
| Lot / Batch ID | #HD0NE923 |
| Measured Potency | 23.89 mg/tab |
| Quality Assessment | Potency verified, purity passed, heavy metals passed. |
| Current Production Batch | Latest Batch |
Verify this result with your scratch-off code at the DPStore register.
Product FAQ
Questions, answered
While both compounds are selective androgen receptor modulators, Ostarine produces more conservative, sustainable lean mass gains with a significantly milder side-effect profile. LGD-4033 is considerably more potent for rapid hypertrophy but carries greater suppression and a higher risk of low-estrogen symptoms. Ostarine is ideal for beginners, those prioritizing joint health, or athletes seeking steady recomposition, whereas LGD-4033 suits advanced users pursuing maximum volumetric growth.
Yes. One of Ostarine's most celebrated properties is its ability to stimulate collagen synthesis and improve bone mineral density, directly supporting tendon, ligament, and articular cartilage health. Users with chronic joint pain, old injuries, or connective tissue overuse frequently report significant symptomatic relief and faster return to full training capacity. A therapeutic dose of 10–15mg daily is often sufficient for these rehabilitative benefits.
For beginners, the ideal introduction stack combines Ostarine at 15–20mg daily with GW501516 (Cardarine) at 10–20mg daily. This pairing delivers mild lean mass accretion, dramatic endurance enhancement, and efficient fat oxidation with a very manageable side-effect burden. No testosterone base is required, and PCT needs are minimal for cycles under 8 weeks, making it an excellent entry point into performance enhancement.
Yes. At a conservative 10–15mg daily, Ostarine serves as an effective PCT bridge compound, helping preserve cycle gains while endogenous testosterone production recovers alongside standard SERM protocols like Nolvadex or Clomid. Its minimal suppression at low doses and anti-catabolic properties make it uniquely suitable for this transitional phase, though higher doses during PCT may complicate hormonal recovery.
Most users report subjective improvements in joint comfort, training pumps, and recovery capacity within the first 7–10 days. Measurable strength increases typically appear by week 2–3, while visible hypertrophic changes and body recomposition effects consolidate between weeks 4 and 8. Connective tissue benefits may take 3–4 weeks to become fully apparent as collagen remodeling progresses.
No. Ostarine is characterized by notably dry gains with minimal extracellular fluid accumulation. Unlike aromatizing compounds that produce estrogen-mediated subcutaneous water retention, MK-2866 increases myofibrillar protein content without significant bloating. This property makes it valuable for athletes seeking a lean, defined aesthetic during both bulking and cutting phases.
Comprehensive metabolic panels should include total and free testosterone, luteinizing hormone, follicle-stimulating hormone, estradiol, lipid profiles (total cholesterol, HDL, LDL, triglycerides), and liver enzymes (ALT, AST). Baseline testing before cycle initiation, mid-cycle assessment at week 4–6, and post-PCT verification provide complete physiological oversight and ensure safe progression.
PCT is strongly recommended for cycles exceeding 8 weeks or utilizing doses above 20mg daily, where suppression becomes clinically significant. For shorter, lower-dose protocols (6–8 weeks at 10–15mg), some users recover naturally without pharmaceutical intervention, though a mild PCT with Tamoxifen at 20/20/10/10mg over four weeks remains prudent insurance. Blood work should always guide the decision.
Yes. Ostarine is among the most female-friendly performance compounds due to its high tissue selectivity and minimal androgenic activity. Women typically respond excellently to conservative doses of 5–10mg daily over 6–8 week cycles. Virilization risk is extremely low at these ranges, though individual sensitivity varies and immediate discontinuation is advised upon any voice changes or clitoral enlargement.
Independent analytical verification confirming 23.89mg per tablet demonstrates Dragon Pharma's commitment to delivering accurately dosed products rather than falling short of label claims. Generic or unverified sources frequently contain 40–70% of stated dosage, or entirely different compounds such as prohormones mislabeled as SARMs. This dosing uncertainty not only compromises hypertrophic and rehabilitative results but introduces unpredictable side effect profiles that verified products avoid.
